Correspondence
Distinguishing optic pathway glioma and retinitis pigmentosa with visual field testing
An 11-year-old boy was referred to the inherited eye disease clinic at the University of Iowa for progressive vision loss OS greater than OD over the past year. The patient denied any peripheral visual field loss, nyctalopia, or photophobia. Multiple family members of both sexes had molecularly confirmed autosomal dominant retinitis pigmentosa (RP) caused by a heterozygous Val87Asp mutation in the rhodopsin gene (Fig. 1A).Erlotinib-associated bilateral anterior uveitis: resolution with posterior sub-Tenon’s triamcinolone without erlotinib cessation
Erlotinib (Tarceva; Genetech USA, Inc, San Francisco, Calif.) is an inhibitor of epidermal growth factor receptor tyrosine kinase that is approved as therapy for patients with non–small cell lung cancer and advanced-stage pancreatic cancer.1–4 It has been associated with anterior uveitis in 2 prior cases.5,6 We report a 77-year-old female with stage IV squamous cell cancer of the lung with liver metastases who was treated with erlotinib starting 6 weeks before the onset of bilateral anterior uveitis.Sustained and expedited resolution of diabetic papillopathy with combined PRP and bevacizumab
Diabetic papillopathy (DP) is a rare condition that occurs in 1.4% of patients with type I and II diabetes.1 It is unilateral in 50% of cases and associated with diabetic retinopathy progression.1 Although it is traditionally a self-limited disease with spontaneous resolution within 3 to 4 months,2,3 it may precede the development of nonarteritic anterior ischemic optic neuropathy, which can result in permanent vision loss. It is controversial whether DP is actually a mild reversible form of nonarteritic anterior ischemic optic neuropathy.Unilateral manifestation of autoimmune retinopathy
Autoimmune retinopathy (AIR) encompasses a spectrum of rare autoimmune diseases, including cancer-associated retinopathy and nonparaneoplastic-associated retinopathy, which primarily affect retinal photoreceptor function, and melanoma-associated retinopathy (MAR), which primarily affects bipolar cell function. Clinical features include panretinal degeneration with no or little pigment deposition, progressive visual field deficits, and photopsias with or without a history of carcinoma or melanoma at the time of ocular presentation.Chronic myelogenous leukemia presenting with bilateral optic disc neovascularization
Clinically evident ocular involvement is common in patients with leukemia and has been described in up to 50% of patients at the time of diagnosis.1 The 2 main types of ocular involvement include direct leukemic infiltration of ocular tissues and secondary leukemic retinopathy (e.g., retinal hemorrhages, cotton wool spots) from hematological complications of leukemia like anemia and hyperviscosity.2 Peripheral neovascularization, secondary to hyperviscosity and capillary nonperfusion, is common in patients with chronic myelogenous leukemia (CML), occurring in approximately 78% of cases.
